TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01125800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
Study: NCT03217500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal epithelial autograft
Description: After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
Study: NCT01125800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
Study: NCT00419731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Placebo, 25 mg, q.d., for 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion + Naltrexone
Description: Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Naltrexone, 25 mg, q.d., for 7 weeks.
Study: NCT03217500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal conjunctival autograft
Description: After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple removal
Description: Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diamond knife
Description: A diamond knife to create a particular shaped limbal graft for transplantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to create a particular shaped graft for transplantation
Study: NCT01686607

Intervention type: DRUG
Intervention: Parenteral micafungin application
Description: Parenteral

Intervention type: DRUG
Intervention: Other parenteral antifungal drugs
Description: Parenteral
Study: NCT00622622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR2-169 and gemcitabine
Description: Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
Study: NCT02961907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEPCI
Description: Both parents will receive:~* consultation with a psychiatrist then psychologist follow-up if required, addiction specialist physician consultation then liaison nurse follow-up if required~* endocrinologist consultation then dietitian follow-up if required~* actiphysician consultation and follow-up if required This program will be added to the usual routine course Both parents will receive a 3 months personalized follow-up if required from the multi disciplinary consultation and before the first ART attempt.
Study: NCT04240899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-yoga
Description: Subjects will undergo 30-minute yoga sessions delivered remotely 2-3 times/week for 6-weeks. The yoga sessions will be delivered one-on-one and will include 5-7 minutes of breathing exercises 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
Study: NCT04014556

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: micropulse laser
Description: Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept
Study: NCT01456351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine plus Rituximab
Description: Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
Description: Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
Study: NCT05590182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.~A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention.
Study: NCT02534363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Oral, dose range 5-30 mg/day, once or twice a day, during study duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Oral, dose range 100-600 mg/day, once or twice a day, during study duration
Study: NCT01065545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
Study: NCT03188250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chama cha Mamtoto
Description: Chama cha Mamatoto is a community-based model of peer support group in pregnancy and infancy that combines health education, relationship building and a savings and loans program, led by community health workers
Study: NCT02534363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Oral, dose range 40-160 mg/day, once or twice a day, during study duration
Study: NCT00525681

Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine A
Description: Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.

Intervention type: DRUG
Group type: OTHER
Intervention: tacrolimus
Description: Dosing of tacrolimus is given twice daily and individualized as per center practice.
Study: NCT03453775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided periradicular lumbar infiltration
Description: Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy guided periradicular lumbar infiltration
Description: Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
Study: NCT03876951

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy
Description: Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery.
Study: NCT02771873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated cardiovascular disease risk management.
Description: Health promotion intervention
Study: NCT03257280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early oral nutrition
Description: An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
Study: NCT00942357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT02534363

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive battery
Description: Completed in the following standardized sequence: 1-the Rey Auditory Verbal Learning Test (RAVLT); 2-WAIS-III digit symbol subtest; 3-Grooved Pegboard Test; 4-The Zoo Map Test; 5-Tower of London Test (ToL); 6-Rey Complex Figure (RCF); 7-Trail Making Test (TMT); 8-WAIS-III digits forward and backward subtests; 9-WAIS-III letter-number sequencing subtest; 10-WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11-Stroop Test; 12-letter (FAS) and semantic (animal) fluency tests; 14-Eyes Task; 15-Continuous Performance Test (CPT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive battery
Description: Completed in the following standardized sequence: 1-the Rey Auditory Verbal Learning Test (RAVLT); 2-WAIS-III digit symbol subtest; 3-Grooved Pegboard Test; 4-The Zoo Map Test; 5-Tower of London Test (ToL); 6-Rey Complex Figure (RCF); 7-Trail Making Test (TMT); 8-WAIS-III digits forward and backward subtests; 9-WAIS-III letter-number sequencing subtest; 10-WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11-Stroop Test; 12-letter (FAS) and semantic (animal) fluency tests; 14-Eyes Task; 15-Continuous Performance Test (CPT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive battery
Description: Completed in the following standardized sequence: 1-the Rey Auditory Verbal Learning Test (RAVLT); 2-WAIS-III digit symbol subtest; 3-Grooved Pegboard Test; 4-The Zoo Map Test; 5-Tower of London Test (ToL); 6-Rey Complex Figure (RCF); 7-Trail Making Test (TMT); 8-WAIS-III digits forward and backward subtests; 9-WAIS-III letter-number sequencing subtest; 10-WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11-Stroop Test; 12-letter (FAS) and semantic (animal) fluency tests; 14-Eyes Task; 15-Continuous Performance Test (CPT).
Study: NCT00066677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuMAB-VEGF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuMAB-VEGF
Study: NCT01708577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Validation of the IPANEMA - measurement system
Description: Control of the body conditions under real life conditions during a sportive activity.
Study: NCT00066677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT04083430

Intervention type: DRUG
Group type: OTHER
Intervention: Yellow Fever Vaccine
Description: STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.~After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.~Powder and solvent for suspension for injection.~Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution.
Study: NCT03863509

Intervention type: BEHAVIORAL
Intervention: Cigarettes
Description: smokes daily

Intervention type: BEHAVIORAL
Intervention: E-Cigarettes
Description: E-cigarette usage \>/= 5 days/week
Study: NCT04807686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory simulation
Description: Each patient will be delivered each of the 2 auditory stimulation protocols considered in the context of the research: stimulation with a traditional algorithm called AT and stimulation with a notched-type algorithm called AE. The order in which will be carried out, for the same patient, each of these 2 protocols (AT then AE or AE then AT) will be randomized.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auditory simulation
Description: Each patient will be delivered each of the 2 auditory stimulation protocols considered in the context of the research: stimulation with a traditional algorithm called AT and stimulation with a notched-type algorithm called AE. The order in which will be carried out, for the same patient, each of these 2 protocols (AT then AE or AE then AT) will be randomized.
Study: NCT01800097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: modafinil
Description: Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
Study: NCT00756366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.

Intervention type: OTHER
Group type: OTHER
Intervention: Positron Emission Tomography
Description: PET scan at baseline and 6-8 weeks, no CPAP therapy
Study: NCT04372251

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus tarsi approach (STA)
Description: Osteosynthesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)
Description: Osteosynthesis
Study: NCT03191266

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: Active rTMS will receive an intermittent rTMS stimulation protocol.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
Study: NCT03066063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCare
Description: The iCare product is an action video game designed to provide home-based vision therapy for non-strabismic amblyopia and convergence insufficiency in children as young as 4 years old. Participants assigned to an iCare group will play iCare vision therapy games for approximately 20 minutes per day, five days per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCare
Description: The iCare product is an action video game designed to provide home-based vision therapy for non-strabismic amblyopia and convergence insufficiency in children as young as 4 years old. Participants assigned to an iCare group will play iCare vision therapy games for approximately 20 minutes per day, five days per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Amblyopia standard of Care
Description: The amblyopia standard of care group will be prescribed patching for two or six hours per day, seven days per week. Standard of care group participants with best-corrected vision worse than 20/200 in their amblyopic eye will be prescribed six hours of patching daily

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CI standard of Care
Description: A dosage-matched CI standard of Care group will be prescribed pencil pushups for 20 minutes per day, five days per week.
Study: NCT03856216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Given IV
Study: NCT04499079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning Health System
Description: This is a system-level intervention designed to improve collaboration among personnel from the juvenile and behavioral healthcare systems.
Study: NCT03856216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT03268616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory threshold load device and NPPV
Description: before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory threshold load device and NPPV
Description: before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive
Study: NCT04347486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection 2mg/kg
Description: Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection 4mg/kg
Description: Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection 8mg/kg
Description: Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular reversal agent injection
Description: Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
Study: NCT04171414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P17 SC AI (adalimumab)
Description: Subcutaneous Injection of Adalimumab 40mg once every two weeks
Study: NCT04187365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of Indwelling Catheter
Description: Foley catheter
Study: NCT03613896

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional dentures
Description: conventional dentures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3d printed denture
Description: construction of a 3d printed denture through a recent method instead of conventional heat processing
Study: NCT02299050

Intervention type: DRUG
Group type: OTHER
Intervention: Cycloset
Description: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
Study: NCT01257269

Intervention type: OTHER
Intervention: Observation
Description: No interventions planned: treatment of patients at the discretion of the treating/responsible physician

Intervention type: OTHER
Intervention: Observation
Description: No interventions planned: treatment of patients at the discretion of the treating/responsible physician
Study: NCT00495391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One oral placebo tablet twice daily for 52 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000 mg (if \<75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 1000 mg (if \<75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Study: NCT00821743

Intervention type: DEVICE
Group type: OTHER
Intervention: Deep brain stimulation electrode
Description: The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
Study: NCT01237119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 1.8 mg once daily, subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide-placebo
Description: 1.8 mg once-daily, subcutaneous injection
Study: NCT04083547

Intervention type: DIAGNOSTIC_TEST
Intervention: iCellate
Description: New method of circulating tumour cell detection and capture.